|
| 37932961 | Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. | Alzheimers Dement | 2024 |
| 37698424 | The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. | Alzheimers Dement | 2024 |
| 35946590 | Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. | Alzheimers Dement | 2023 |
| 37458272 | Trial of Solanezumab in Preclinical Alzheimer's Disease. | N Engl J Med | 2023 |
| 36946443 | Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. | J Prev Alzheimers Dis | 2023 |
| 37202518 | Detection and treatment of Alzheimer's disease in its preclinical stage. | Nat Aging | 2023 |
| 36748826 | Expectations and clinical meaningfulness of randomized controlled trials. | Alzheimers Dement | 2023 |
| 36710683 | Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease. | J Alzheimers Dis | 2023 |
| 36627206 | Natural cubic splines for the analysis of Alzheimer's clinical trials. | Pharm Stat | 2023 |
| 35971310 | The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. | Alzheimers Dement | 2023 |
| 36209495 | Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. | Alzheimers Dement | 2023 |
| 35962782 | Tau positron emission tomography in preclinical Alzheimer's disease. | Brain | 2023 |
| 34043269 | State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. | Alzheimers Dement | 2022 |
| 35379951 | Early-stage Alzheimer disease: getting trial-ready. | Nat Rev Neurol | 2022 |
| 35440022 | Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. | Alzheimers Res Ther | 2022 |
| 35768339 | Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. | Alzheimers Dement | 2022 |
| 35580594 | Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. | Brain | 2022 |
| 35542998 | Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. | J Prev Alzheimers Dis | 2022 |
| 35542991 | Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. | J Prev Alzheimers Dis | 2022 |
| 36471006 | Editorial: We Have Turned the Corner. | J Prev Alzheimers Dis | 2022 |
| 36336171 | Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review. | Ageing Res Rev | 2022 |
| 35224459 | Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trials. | JAMIA Open | 2022 |
| 35156002 | ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trails. | JAMIA Open | 2022 |
| 35155730 | Impact of sex and <i>APOE</i> ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults. | Alzheimers Dement (Amst) | 2022 |
| 35098978 | The Ups and Downs of Amyloid in Alzheimer's. | J Prev Alzheimers Dis | 2022 |
| 35213778 | Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). | Alzheimers Dement | 2022 |
| 35197359 | Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study. | Neurology | 2022 |
| 34581485 | Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. | Alzheimers Dement | 2022 |
| 33971962 | Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. | Alzheimers Res Ther | 2021 |
| 33682706 | The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. | J Alzheimers Dis | 2021 |
| 33842885 | Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. | Brain Commun | 2021 |
| 33778148 | Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. | Alzheimers Dement (N Y) | 2021 |
| 33551954 | Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. | Front Neurol | 2021 |
| 34585227 | Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. | J Prev Alzheimers Dis | 2021 |
| 34585209 | Editorial: How Will Aducanumab Approval Impact AD Research? | J Prev Alzheimers Dis | 2021 |
| 34430703 | Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. | Alzheimers Dement (Amst) | 2021 |
| 34661109 | Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. | Sleep Adv | 2021 |
| 34018654 | The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. | Alzheimers Dement | 2021 |
| 34155411 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. | Nat Med | 2021 |
| 34101785 | The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program. | J Prev Alzheimers Dis | 2021 |
| 34101788 | Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. | J Prev Alzheimers Dis | 2021 |
| 34101778 | New Hope for Alzheimer's Disease. | J Prev Alzheimers Dis | 2021 |
| 34101781 | Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. | J Prev Alzheimers Dis | 2021 |
| 34101779 | Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. | J Prev Alzheimers Dis | 2021 |
| 34366337 | Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. | J Alzheimers Dis | 2021 |
| 32568366 | Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. | JAMA Neurol | 2020 |
| 33253354 | BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. | Brain | 2020 |
| 33163609 | Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. | Alzheimers Dement (Amst) | 2020 |
| 33049114 | Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. | Alzheimers Dement | 2020 |
| 32920625 | The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. | J Prev Alzheimers Dis | 2020 |